EPMC Pharma will help you to bring your medicinal products faster on the market



EPMC Pharma, a newly created private Company based in Brussels (Belgium), offers expertise in European Medical, Pharmaceutical and Regulatory Affairs.


What can offer EPMC Pharma ?

·          A team of highly qualified professionals (Lawyers, MDs, PharmDs, PhDs, ... ) with significant experience in big Pharma Companies, Regulatory Agencies and Universities

·          A network of the best European Experts specialised in Medicinal Product Development, Regulatory Affairs and R&D Strategies

·          A group of lawyers specialised in Pharmaceutical Law, Intellectual Property, Patents and Supplementary Protection Certificates

·          Selection of highly qualified personnel in the field of Medicinal Product Development

·          Access to European Research Networks:

Ø       Pharmaceutical Development

Ø       Clinical Research


How will EPMC Pharma help you to facilitate the access to the market of your medicinal products?


·          Designing Product Development Plans

·          Optimising Regulatory Strategies

·          Facilitating the Pharmaceutical Development

Ø       Innovative formulations and presentations

Ø       Preparation, submission and follow·up of Clinical Trial Applications

Ø       Access to Clinical Research networks

·          Preparing and organising European Regulatory Procedures

Ø       Scientific Advice

Ø       SME designation

Ø       Orphan Drug Designation

Ø       Marketing Authorisation Procedures

-            Centralised Procedure

-            Decentralised and Mutual Recognition Procedures

·          Providing legal advice on issues related to Pharmaceutical Law, Intellectual Property, Patents and Supplementary Protection Certificates

Ø       Focusing on Development of Medicinal Products for Paediatric Use

Ø       Scientific Advice for Paediatric Development

Ø       Paediatric Investigation Plans

·          Preparation, submission and validation at the EMEA

Ø       Clinical studies in children

Ø       Paediatric Use Marketing Authorisation (PUMA) Applications

Ø       Submission of applications for the incentives offered by the new European Paediatric Regulation


For further information, please contact:

Jean-Pierre Osselaere, PhD
Managing Director, EPMC Pharma
Associate Professor
College of Pharmacy and Biological Sciences University of Lille 2 (France)

Postal address : Waterhoenlaan, 5    B-1860 Meise (Belgium)
Phone: +32 475 740556
Fax: + 32 2 2702618
E-mail: info@epmc-pharma.com